117013-33-9Relevant articles and documents
Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis
Procopiou, Panayiotis A.,Ford, Alison J.,Gore, Paul M.,Hancock, Ashley P.,Hodgson, Simon T.,Holmes, Duncan S.,Looker, Brian E.,Vile, Sadie,Clark, Kenneth L.,Saunders, Ken A.,Slack, Robert J.,Watts, Clarissa J.
, p. 4914 - 4919 (2017/09/29)
A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, and was turned over to five major metabolites. Furthermore, 33b had longer duration of action than azelastine in guinea pigs, lower rat brain-penetration, and did not cause time dependent inhibition of CYP2D6 or CYP3A4. The clinical dose in humans is expected to be low (approximately 0.5 mg per day) based on the clinical dose used for azelastine and a comparison of efficacy data from animal models for 33b and azelastine.
Compounds
-
Page/Page column 26, (2009/10/31)
The present invention relates to a compound which is N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide and salts thereof, processes for its preparation, to compositions containing it and to its use in the treatment of various diseases, such as allergic rhinitis.
